The Lantern is billed as an AI platform to accelerate revenue workflows, with claims of 28% faster deal velocity and automated outreach. A Champion Agent tracks job changes across the customer base to automate outreach for certain teams. Lantern Pharma reports progress in 2026, reducing R&D spend by 47% while progressing clinical programs, launching an AI platform with Zeta.ai and expanding an AI Center of Excellence in India. These items illustrate Lantern's expansion into AI-driven sales intelligence, with ongoing financing activities to support growth.
Disciplined Execution Drives 47% Reduction in R&D Spend While Advancing Multiple Clinical Programs, Launching Multi-Agentic AI Platform withZeta.ai Commercially, and Strengthening Balance Sheet with Financing of up to $9.25 Million Q1 net loss reduced 27% year-over-year while progressing multiple...
www.pharmiweb.comLantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company leveraging its proprietary RADR® artificial intelligence (AI) and machine learning (ML) platform to transform...
www.innovationopenlab.comnews
www.newswire.calantern News and Updates from The Economictimes.com
economictimes.indiatimes.comBrowse, deploy, and customize AI agents that automate every critical revenue function—from champion tracking to intent monitoring, all available in minutes.
withlantern.comDisciplined Execution Drives 47% Reduction in R&D Spend While Advancing Multiple Clinical Programs, Launching Multi-Agentic AI Platform withZeta.ai Commercially, and Strengthening Balance Sheet with Financing of up to $9.25 Million
natlawreview.com